Almirall again receives the ISO 14001:2004 Environmental management certificate
Almirall centres that received the certificate in 2004 are once again recognised and the new Sant Feliu R&D centre is included
This re-certification now includes the company’s new R&D centre located in Sant Feliu de Llobregat (
The aspect evaluated in the Almirall centres receiving the ISO 14001:2004 certificate was the environmental management system of the whole company as part of its continuous improvement programme. This system affords order and coherence in environmental issues by distributing resources, sharing responsibilities and the continuous assessment of practices, procedures and working methods within a framework of environmental respect.
Almirall and the environment
The ISO 14001:2004 certification denotes Almirall’s progression in its environmental policy. All company premises enjoy cutting-edge analytical and experimentation equipment and systems and their conditioning ensures a respect for the environment.
The scope of this certificate affects management, central commercial services, (national and international), regulatory affairs, research and development of new drugs, manufacturing of pharmaceutical specialities and active ingredients for the pharmaceutical plants.
In line with Almirall’s policy, reduction and elimination of waste products is included as one more stage in the production process, as well as implanting all necessary measures to prevent accidents that might affect human health and/or the environment.
The environmental policy is dynamic as it seeks new solutions to improve processes, products and services through the permanent updating of measures to ensure they are efficient and can adapt to climate changes.
Almirall conveys this commitment to all staff members to promote awareness of its importance and its inclusion in day-to-day work. It also demands compliance from external companies working in Almirall centres.
About Almirall
Almirall, a leading company committed to health, is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed drugs with the aim of improving people’s health and quality of life.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis, rheumatoid arthritis and multiple sclerosis.
Almirall is currently present in over 80 countries. The company has direct presence in
For more information:
Ketchum/SEIS
Sonia San Segundo / Victoria Hernández
Tel.: 91 788 32 00
Note
This document is a press release and not a prospectus. Investors should not therefore acquire or apply for any shares or other securities mentioned herein without having previously consulted the information contained within the official prospectus approved by the Spanish Stock Exchange Commission on 31 May. This prospectus is available to the public at the Spanish Securities Commission website (www.cnmv.es) and from the company itself (www.almirall.es).Copies of the official prospectus will also be available free of charge from company headquarters.
This document should in no way be construed as an offer or invitation to treat, nor does it represent an offer to buy or subscribe to shares in the Company. Likewise, the contents of this document and the fact that it has been distributed must not be used as, or form the basis for, any kind of contract or decision to invest and do not constitute any recommendation as regards the securities of the Company.
This communication is intended solely for people living outside the
The information contained herein does not constitute an offer of securities in the
Finally, neither this document nor any copy thereof may be taken or transmitted to the United States of America, Canada, Australia or Japan or be distributed, either directly or indirectly, in the United States of America, Canada, Australia or Japan or given to residents of any of these countries.